Prime-boost vaccination with recombinant H5-fowlpox and newcastle disease virus vectors affords lasting protection in SPF muscovy ducks against highly pathogenic H5N1 influenza virus

Vaccine

Volumn 31, Issue 38, 2013, Pages 4121-4128

  Niqueux, Éric ^a   Guionie, Olivier ^a   Amelot, Michel ^a   Jestin, Véronique ^a  

^a FRENCH AGENCY FOR FOOD   (France)

Author keywords

Fowlpox; Highly pathogenic H5N1 avian influenza; Muscovy ducks; Newcastle disease virus; Protection

Indexed keywords

ANTIBODY; AVIAN INFLUENZA VACCINE; AVINEW; FOWLPOX VIRUS VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEWCASTLE DISEASE VACCINE; RE 5; RECOMBINANT VACCINE; TROVAC AIV H5; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BRAIN; CLADISTICS; CONTROLLED STUDY; DRUG EFFICACY; DUCK; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETIC REASSORTMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H5N8; MORBIDITY; MORTALITY; NONHUMAN; OROPHARYNX; PRIORITY JOURNAL; PROTECTION; SINGLE DRUG DOSE; SURVIVAL; VIRUS DETECTION; VIRUS GENE; VIRUS SHEDDING; VIRUS STRAIN; VIRUS VIRULENCE;

FOWLPOX; HIGHLY PATHOGENIC H5N1 AVIAN INFLUENZA; MUSCOVY DUCKS; NEWCASTLE DISEASE VIRUS; PROTECTION;

ANIMALS; BRAIN; DUCKS; FOWLPOX; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; NEWCASTLE DISEASE VIRUS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRUS SHEDDING;

EID: 84881545779     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.074     Document Type: Article

References (40)

1. Alexander A review of avian influenza in different bird species. Vet Microbiol 2000, 74:3-13.
2. Keawcharoen J., van Riel D., van Amerongen G., Bestebroer T., Beyer W.E., van Lavieren R., et al. Wild ducks as long-distance vectors of highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis 2008, 14:600-607.
3. Kim J.K., Negovetich N.J., Forrest H.L., Webster R.G. Ducks: the "Trojan Horses" of H5N1 influenza. Influenza Other Respi Viruses 2009, 3:121-128.
4. Olsen B., Munster V.J., Wallensten A., Waldenström J., Osterhaus A.D.M.E., Fouchier R.A.M. Global patterns of influenza A virus in wild birds. Science 2006, 312:384-388.
5. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
6. Sturm-Ramirez K.M., Ellis T., Bousfield B., Bissett L., Dyrting K., Rehg J.E., et al. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. J Virol 2004, 78:4892-4901.
7. Swayne D.E. Understanding the complex pathobiology of high pathogenicity avian influenza viruses in birds. Avian Dis 2007, 51:242-249.
8. Hulse-Post D.J., Sturm-Ramirez K.M., Humberd J., Seiler P., Govorkova E.A., Krauss S., et al. Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci USA 2005, 102:10682-10687.
9. Sturm-Ramirez K.M., Hulse-Post D.J., Govorkova E.A., Humberd J., Seiler P., Puthavathana P., et al. Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia?. J Virol 2005, 79:11269-11279.
10. Cagle C., Wasilenko J., Adams S.C., Cardona C.J., To T.L., Nguyen T., et al. Differences in pathogenicity, response to vaccination, and innate immune responses in different types of ducks infected with a virulent H5N1 highly pathogenic avian Influenza virus from Vietnam. Avian Dis 2012, 56:479-487.
11. Kim J.-K., Seiler P., Forrest H.L., Khalenkov A.M., Franks J., Kumar M., et al. Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. J Virol 2008, 82:11374-11382.
12. Löndt B.Z., Nunez A., Banks J., Nili H., Johnson L.K., Alexander D.J. Pathogenesis of highly pathogenic avian influenza A/turkey/Turkey/1/2005 H5N1 in Pekin ducks (Anas platyrhynchos) infected experimentally. Avian Pathol 2008, 37:619-627.
13. Pantin-Jackwood M.J., Suarez D.L., Spackman E., Swayne D.E. Age at infection affects the pathogenicity of Asian highly pathogenic avian influenza H5N1 viruses in ducks. Virus Res 2007, 130:151-161.
14. Phuong D.Q., Dung N.T., Jørgensen P.H., Handberg K.J., Vinh N.T., Christensen J.P. Susceptibility of Muscovy (Cairina moschata) and mallard ducks (Anas platyrhynchos) to experimental infections by different genotypes of H5N1 avian influenza viruses. Vet Microbiol 2011, 148:168-174.
15. Steensels M., Bublot M., Van Borm S., De Vriese J., Lambrecht B., Richard-Mazet A., et al. Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 2009, 27:646-654.
16. Ferreira H.L., Pirlot J.F., Reynard F., van Den Berg T., Bublot M., Lambrecht B. Immune responses and protection against H5N1 highly pathogenic avian Influenza virus induced by the Newcastle disease virus H5 vaccine in ducks. Avian Dis 2012, 56:940-948.
17. Guionie O., Guillou-Cloarec C., Courtois D., Bougeard S., Amelot M., Jestin V. Experimental Infection of Muscovy ducks with highly pathogenic avian influenza virus (H5N1) belonging to clade 2.2. Avian Dis 2010, 54:538-547.
18. Steensels M., Van Borm S., Lambrecht B., De Vriese J., Le Gros F.X., Bublot M., et al. Efficacy of an inactivated and a fowlpox-vectored vaccine in Muscovy ducks against an Asian H5N1 highly pathogenic avian influenza viral challenge. Avian Dis 2007, 51:325-331.
19. Swayne D.E. Impact of vaccines and vaccination on global control of avian influenza. Avian Dis 2012, 56:818-828.
20. Koch G., Steensels M., Van Den Berg T. Vaccination of birds other than chickens and turkeys against avian influenza. OIE Rev Sci Tech 2009, 28:307-318.
21. Beato M.S., Toffan A., De Nardi R., Cristalli A., Terregino C., Cattoli G., et al. A conventional, inactivated oil emulsion vaccine suppresses shedding and prevents viral meat colonisation in commercial (Pekin) ducks challenged with HPAI H5N1. Vaccine 2007, 25:4064-4072.
22. Boltz D.A., Douangngeun B., Sinthasak S., Phommachanh P., Midouangchanh P., Walker D., et al. Field assessment of an H5N1 inactivated vaccine in chickens and ducks in Lao PDR. Arch Virol 2009, 154:939-944.
23. Eggert D., Swayne D.E. Single vaccination provides limited protection to ducks and geese against H5N1 high pathogenicity avian influenza virus. Avian Dis 2010, 54:1224-1229.
24. Middleton D., Bingham J., Selleck P., Lowther S., Gleeson L., Lehrbach P., et al. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks. Virology 2007, 359:66-71.
25. Pfeiffer J., Suarez D.L., Sarmento L., To T.L., Nguyen T., Pantin-Jackwood M.J. Efficacy of commercial vaccines in protecting chickens and ducks against H5N1 highly pathogenic avian influenza viruses from Vietnam. Avian Dis 2010, 54:262-271.
26. Rudolf M., Pöppel M., Fröhlich A., Mettenleiter T., Beer M., Harder T. Efficacy of a commercial inactivated H5 influenza vaccine against highly pathogenic avian influenza H5N1 in waterfowl evaluated under field conditions. OIE Rev Sci Tech 2009, 28:275-291.
27. van der Goot J.A., van Boven M., Stegeman A., van de Water S.G., de Jong M.C., Koch G. Transmission of highly pathogenic avian influenza H5N1 virus in Pekin ducks is significantly reduced by a genetically distant H5N2 vaccine. Virology 2008, 382:91-97.
28. Webster R.G., Webby R.J., Hoffmann E., Rodenberg J., Kumar M., Chu H.J., et al. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens. Virology 2006, 351:303-311.
29. Prel A., Le Gall-Reculé G., Cherbonnel M., Grasland B., Amelot M., Jestin V. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis 2007, 51:484-489.
30. Bublot M., Richard-Mazet A., Chanavat-Bizzini S., Le Gros F.X., Duboeuf M., Stoll A., et al. Immunogenicity of poxvirus vector avian influenza vaccines in Muscovy and Pekin ducks. Avian Dis 2010, 54:232-238.
31. Liu J., Chen P., Jiang Y., Wu L., Zeng X., Tian G., et al. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 2011, 85:10989-10998.
32. Tripathy D.N., Reed W.M. Pox. Diseases of Poultry 2008, 291-307. Blackwell Publishing, Ames, IA, (Chapter 10). 12th ed. Y.M. Saif (Ed.).
33. Bublot M., Pritchard N., Swayne D.E., Selleck P., Karaca K., Suarez D.L., et al. Development and use of fowlpox vectored vaccines for avian influenza. Ann N Y Acad Sci 2006, 1081:193-201.
34. Chen H. Avian influenza vaccination: the experience in China. OIE Rev Sci Tech 2009, 28:267-274.
35. Le Gall-Recule G., Briand F.X., Schmitz A., Guionie O., Massin P., Jestin V. Double introduction of highly pathogenic H5N1 avian influenza virus into France in early 2006. Avian Pathol 2008, 37:15-23.
36. CEC Commission Decision 2006/437/EC of 4 August 2006 approving a diagnostic manual for avian influenza as provided for in Council Directive 2005/94/EC. Official J Eur Union 2006, L237:1-27.
37. OIE Avian influenza. Manual of diagnostic tests and vaccines for terrestrial animals 2012 2012, OIE, W.O.f.A.H., Paris, Available from:, [cited 20.02.13, Chapter 2.3.4]. http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.03.04_AI.pdf.
38. OIE Newcastle disease. Manual of diagnostic tests and vaccines for terrestrial animals 2012 2012, OIE, W.O.f.A.H., Paris, Available from:, [cited 2013 Feb 20, Chapter 2.3.14]. http://www.oie.int/fileadmin/home/eng/health_standards/tahm/2.03.14_newcastle_dis.pdf.
39. Cagle C., To T.L., Nguyen T., Wasilenko J., Adams S.C., Cardona C.J., et al. Pekin and Muscovy ducks respond differently to vaccination with a H5N1 highly pathogenic avian influenza (HPAI) commercial inactivated vaccine. Vaccine 2011, 29:6549-6557.
40. Woodland Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25:98-104.